Artwork

Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Player FM - Aplikasi Podcast
Offline dengan aplikasi Player FM !

Kurt A. Schalper, MD, PhD - Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

1:27:52
 
Bagikan
 

Manage episode 333454473 series 2771425
Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a recent live web broadcast, will provide essential updates and practical guidance regarding biomarker testing and individualized treatment of patients with HER2-altered cancers, and novel targets such as HER3 and TROP2 will be explored as well. Upon completion of this activity, participants should be better able to: Identify patients with solid tumors with HER2, HER3, and TROP2 alterations using established and emerging testing approaches, Incorporate therapies directed at HER2, HER3, and TROP2 into the treatment of patients with tumors with targetable alterations based on the characteristics, mechanisms of action, and latest clinical evidence on approved and emerging therapies, Develop individualized management plans that leverage predictive testing, the most recent clinical findings, and multidisciplinary team-based care in accordance with the latest treatment guidelines and recommendations for patients with solid tumors with HER2, HER3, and TROP2 alterations, either in the context of clinical practice or clinical trials.
  continue reading

313 episode

Artwork
iconBagikan
 
Manage episode 333454473 series 2771425
Konten disediakan oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Semua konten podcast termasuk episode, grafik, dan deskripsi podcast diunggah dan disediakan langsung oleh PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education atau mitra platform podcast mereka. Jika Anda yakin seseorang menggunakan karya berhak cipta Anda tanpa izin, Anda dapat mengikuti proses yang dijelaskan di sini https://id.player.fm/legal.
Go online to PeerView.com/EZK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Detecting molecular alterations driving the development of specific cancers and then targeting these alterations with matched therapies or combinatorial approaches is now the standard of care for many cancers. HER2 alterations have been identified as key therapeutic targets in breast, gastrointestinal, lung, and other cancers, and targeting these alterations with antibody–drug conjugates (ADCs), antibodies, more specific tyrosine kinase inhibitors, and bispecific antibodies are improving outcomes. In addition to HER2, HER3 represents an emerging target in several cancer types for which novel targeted therapies are being developed, and targeting TROP2 is showing promise as well. Given these treatment advances, biomarker testing to identify patients who may benefit the most from HER2-, HER3-, and TROP2-targeted therapies has never been more important. This activity, based on a recent live web broadcast, will provide essential updates and practical guidance regarding biomarker testing and individualized treatment of patients with HER2-altered cancers, and novel targets such as HER3 and TROP2 will be explored as well. Upon completion of this activity, participants should be better able to: Identify patients with solid tumors with HER2, HER3, and TROP2 alterations using established and emerging testing approaches, Incorporate therapies directed at HER2, HER3, and TROP2 into the treatment of patients with tumors with targetable alterations based on the characteristics, mechanisms of action, and latest clinical evidence on approved and emerging therapies, Develop individualized management plans that leverage predictive testing, the most recent clinical findings, and multidisciplinary team-based care in accordance with the latest treatment guidelines and recommendations for patients with solid tumors with HER2, HER3, and TROP2 alterations, either in the context of clinical practice or clinical trials.
  continue reading

313 episode

모든 에피소드

×
 
Loading …

Selamat datang di Player FM!

Player FM memindai web untuk mencari podcast berkualitas tinggi untuk Anda nikmati saat ini. Ini adalah aplikasi podcast terbaik dan bekerja untuk Android, iPhone, dan web. Daftar untuk menyinkronkan langganan di seluruh perangkat.

 

Panduan Referensi Cepat